Novartis tests new hope for sickle cell patients
NCT ID NCT06546670
Summary
This is the first study of a new drug called ITU512 for sickle cell disease. Researchers will first test its safety in healthy adults, then see if it can help patients by boosting a protective type of hemoglobin. The goal is to see if the drug can safely control the disease and reduce its complications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Quotient Sciences Sea View
RECRUITINGMiami, Florida, 33126, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.